Loading...
Please wait, while we are loading the content...
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
| Content Provider | Europe PMC |
|---|---|
| Author | Subbiah, V. Kuravi, S. Ganguly, S. Welch, D.R. Vivian, C.J. Mushtaq, M.U. Hegde, A. Iyer, S. Behrang, A. Ali, S.M. Madison, R.W. Venstrom, J.M. Jensen, R.A. McGuirk, J.P. Amin, H.M. Balusu, R. |
| Copyright Year | 2021 |
| Journal | ESMO Open |
| Volume Number | 6 |
| PubMed Central reference number | PMC8271116 |
| Issue Number | 4 |
| PubMed reference number | 34242968 |
| e-ISSN | 20597029 |
| DOI | 10.1016/j.esmoop.2021.100172 |
| Language | English |
| Publisher | BMJ |
| Publisher Date | 2021-07-07 |
| Access Restriction | Open |
| Rights License | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2021 The Authors |
| Subject Keyword | precision medicine NPM1-ALK+ ALCL ALK inhibitor apoptosis clinical trial complete response |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |